Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
stocks
ASX retail share remains cheap despite weaker earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,712.80 | 44.30 | 0.51% |
| CAC 40 | 7,701.95 | 67.36 | -0.87% |
| DAX 40 | 22,300.75 | 312.22 | -1.38% |
| Dow JONES (US) | 45,166.64 | 793.47 | -1.73% |
| FTSE 100 | 9,967.35 | 4.82 | -0.05% |
| HKSE | 24,951.88 | 95.45 | 0.38% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 53,373.07 | 230.58 | -0.43% |
| NZX 50 Index | 12,935.39 | 41.60 | -0.32% |
| S&P 500 | 6,368.85 | 108.31 | -1.67% |
| S&P/ASX 200 | 8,516.30 | 44.70 | 0.53% |
| SSE Composite Index | 3,913.72 | 24.64 | 0.63% |